share_log

Recursion Pharmaceuticals | 8-K: Current report

Recursion Pharmaceuticals | 8-K: Current report

Recursion Pharmaceuticals | 8-K：重大事件
美股SEC公告 ·  10/02 20:04

牛牛AI助理已提取核心訊息

On October 2, 2024, Recursion Pharmaceuticals, Inc., a clinical stage TechBio company, announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for REC-1245, a potential first-in-class RBM39 Degrader aimed at treating biomarker-enriched solid tumors and lymphoma. The company plans to initiate a Phase 1/2 clinical trial in Q4 2024 to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and potential efficacy of REC-1245 as a monotherapy. REC-1245 was developed using Recursion's AI-enabled platform, which facilitated the identification and optimization of the drug candidate in under 18 months, significantly faster than the industry average. The company's platform leverages machine learning algorithms and one of the world's most powerful supercomputers to analyze vast biological and chemical datasets. Recursion Pharmaceuticals, headquartered in Salt Lake City, is also a founding member of BioHive, the Utah life sciences industry collective.
On October 2, 2024, Recursion Pharmaceuticals, Inc., a clinical stage TechBio company, announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for REC-1245, a potential first-in-class RBM39 Degrader aimed at treating biomarker-enriched solid tumors and lymphoma. The company plans to initiate a Phase 1/2 clinical trial in Q4 2024 to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and potential efficacy of REC-1245 as a monotherapy. REC-1245 was developed using Recursion's AI-enabled platform, which facilitated the identification and optimization of the drug candidate in under 18 months, significantly faster than the industry average. The company's platform leverages machine learning algorithms and one of the world's most powerful supercomputers to analyze vast biological and chemical datasets. Recursion Pharmaceuticals, headquartered in Salt Lake City, is also a founding member of BioHive, the Utah life sciences industry collective.
2024年10月2日，處於臨床階段的科技生物公司Recursion Pharmaceuticals, Inc.宣佈，美國食品和藥品監督管理局（FDA）已批准 REC-1245 的新藥申請。此藥爲首個針對治療生物標誌物富集的實體瘤和淋巴瘤的一類RBM39降解劑。該公司計劃在 2024年第四季度開始進行1/2期臨床試驗，評估 REC-1245 作爲單藥物治療的安全性、耐受性、藥代動力學、藥效動力學和潛在療效。REC-1245 是利用 Recursion 的人工智能平台開發的，該平台在不到18個月內完成了該藥物候選化合物的確定和優化，比行業平均水平快得多。該公司的平台利用機器學習算法和全球最強大的超級計算機之一，分析龐大的生物和化學數據集。總部位於鹽湖城的 Recursion Pharmaceuticals 還是 Utah 生命科學行業聯合體 BioHive 的創始成員。
2024年10月2日，處於臨床階段的科技生物公司Recursion Pharmaceuticals, Inc.宣佈，美國食品和藥品監督管理局（FDA）已批准 REC-1245 的新藥申請。此藥爲首個針對治療生物標誌物富集的實體瘤和淋巴瘤的一類RBM39降解劑。該公司計劃在 2024年第四季度開始進行1/2期臨床試驗，評估 REC-1245 作爲單藥物治療的安全性、耐受性、藥代動力學、藥效動力學和潛在療效。REC-1245 是利用 Recursion 的人工智能平台開發的，該平台在不到18個月內完成了該藥物候選化合物的確定和優化，比行業平均水平快得多。該公司的平台利用機器學習算法和全球最強大的超級計算機之一，分析龐大的生物和化學數據集。總部位於鹽湖城的 Recursion Pharmaceuticals 還是 Utah 生命科學行業聯合體 BioHive 的創始成員。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間